Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Subscribe To Our Newsletter & Stay Updated
